28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Study objective To examine the risks and compare the occurrences of major long-term side effects (sexual dysfunction, bone fractures, diabetes, cardiovascular morbidity, acute myocardial infarction [MI], and dementia) in patients with prostate cancer who received androgen-deprivation therapy (ADT) with those who did not. 5 key findings →
Design: cohort study Participants: 201,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings demonstrate the importance of community-based patient-centered care strategies for stroke survivors that address their range of health needs and prevent more costly acute care use. 2 key findings →
Design: cohort study Participants: 29,673 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among older Medicare beneficiaries with heart failure, there is a higher overall burden of comorbidity and greater prevalence of discordant comorbidity among the oldest old. 5 key findings →
Design: cohort study Participants: 201,130 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The findings of this large cohort study suggest that system-level measurement and reporting of specific low-value services is feasible, enables cross-system comparisons, and reveals a broad range of low-value care use. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Men, racial and ethnic minority individuals, older adults, and those with language barriers are at increased risk for undertreatment of depression. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The impact of comorbidities present at the time of transplantation changes with time after transplantation. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Illness duration and symptom prevalence, duration, and burden were analysed for children testing positive for SARS-CoV-2 for whom illness duration could be determined, and were assessed overall and for younger (age 5-11 years) and older (age 12-17 years) groups. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Repeat HF hospitalizations remain a strong predictor of mortality for existing patients with HF. 3 key findings →
Participants: 51,286 Evidence: moderate
Full summary, score breakdown and related studies → Original source
GIM services care for a markedly heterogeneous population but the most common conditions were similar across 7 hospitals. 3 key findings →
Design: cross-sectional Participants: 223 Evidence: low
Full summary, score breakdown and related studies → Original source
The use of methods that focus on determining a single underlying cause may lead to underestimation of the extent of the contribution of some diseases such as dementia and respiratory disease to death in older adults and overestimation of the contribution of other diseases. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Claims data studies that include indicators of potentially diminished patient functional status better capture heterogeneity of patients with multiple chronic conditions. 1 key finding →
Participants: 72,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Men with prostate cancer treated with androgen deprivation therapy had a higher likelihood of developing new comorbidities than men who did not receive androgen deprivation therapy. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The authors identified several factors, including receipt of mechanical ventilation, which were significantly associated with increased long-term mortality for survivors of severe sepsis. 5 key findings →
Participants: 2,727 Evidence: low
Full summary, score breakdown and related studies → Original source
The CPCSSN diagnostic algorithms showed excellent sensitivity and specificity for hypertension, diabetes, epilepsy, and parkinsonism and acceptable values for the other conditions. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Multiple EHR components provide a more consistent and higher performance than a single one for the selected phenotypes. 5 key findings →
Participants: 175 Evidence: low
Full summary, score breakdown and related studies → Original source
The Ministry of Health, Labor, and Welfare, Japan, launched the Diagnosis Procedure Combination system in 2002. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this large population-based study, the overall prevalence of Whipple's disease in the USA is 9.8 cases per 1 million people. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The QICDSS provides a way of producing population-based data on the chronic disease burden, health services and prescription drug uses. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The objective of this study was to determine the accuracy of administrative data (by use of hospital discharge codes) for measuring comorbidity in patients with heart disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reasonable prognostic information for 1-year mortality in older patients discharged from general medicine services can be derived from administrative data to identify high-risk groups of persons. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Only about one-third of individuals with COPD in Ontario, Canada, received PFT to confirm their diagnosis; age, comorbidity, and physician factors appear to influence its use. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with peripheral artery disease (PAD), chronic limb-threatening ischemia (CLTI), and/or diabetic foot ulcer (DFU) are at increased risk for limb loss and death. 3 key findings →
Participants: 178,995 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →